Overview

• US biopharma firm's Q1 revenue rose on YUTREPIA sales, third straight profitable quarter

• EPS for Q1 beat analyst expectations

• Company saw increased patient uptake and more prescribers for YUTREPIA since launch

Outlook

• Company did not provide specific financial or quantitative guidance for future quarters or full year in its press release

Result Drivers

• YUTREPIA LAUNCH - Q1 revenue and profitability driven by continued uptake and sales of YUTREPIA following its launch in June 2025

• PATIENT UPTAKE - Company reported more than 4,500 unique patient prescriptions and approximately 3,750 patients treated since launch, with strong prescription-to-start conversion rates

Company press release: ID:nGNX7bTPVg

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS	Beat	$0.52	$0.41 (8 Analysts)
Q1 Operating Income		$61.5 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Liquidia Corp is $54.00, about 27.7% above its May 8 closing price of $42.30

• The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.